Results of our pilot survey on adherence just published in "Journal of Patient Compliance" (Vol 2 Issue 4)

The "Journal of Patient Compliance" (Vol 2 Issue 4) has just published our scientific article on the patient-driven pilot survey on adherence in CML:

Optimal jpccoveradherence to oral cancer therapy is of key importance to maximise treatment effectiveness in patients. With the advance of molecular target therapies, cancer treatment in more and more indications is transforming from in-hospital care towards oral treatment in an outpatient setting. With cancer becoming a chronic disease, patients are often required to take the drug indefinitely on a daily basis. Ensuring an optimal adherence to treatment over the long-term period could be a challenge. As data on the driving factors of nonadherence in oncology is scarce, a pan-European workgroup of the CML Advocates Network has conducted a pilot study which has unveiled differences of non-adherence between countries, administration types and use of adherence tools in Chronic Myeloid Leukemia. This pilot study has provided the groundwork for a larger global adherence study that is currently ongoing in 12 languages.


Read the full text here:

Link to the global survey

Scientific reference of this article

  • Adherence in Chronic Myeloid Leukemia: Results of a Patient-driven Pilot Survey, Jan Geissler, Giora Sharf, Journal For Patient Compliance, Vol 2 Issue 4 (published online on 12 Dec 2012)







EU e-Privacy Directive

Please donate!

Please donate!


Tweet Feed

Check our global database run by patients for #patients with 51 current #CML #clinicaltrials which have been initia……

Thursday, 24 May 2018

“When looking at statistics, it is important to remember that we are not talking about decimal points on a graph, b……

Retweeted Thursday, 24 May 2018

From 26 April “Sprycel is indicated for the treatment of paediatric patients with: newly diagnosed Ph+ CML in chron……

Retweeted Saturday, 19 May 2018